文献速递肝肾功能剂量调整药物相互作用抗栓抗凝管理

达比加群与P-gp介导药代动力学增强剂合用在肾功能不全患者的定量获益-风险评价

Quantitative Benefit-Risk Assessment of P-gp-Mediated Drug-Drug Interactions of Dabigatran Coadministered With Pharmacokinetic Enhancers in Patients With Renal Impairment.
PubMed 文献 · Clin Pharmacol Ther · 2020-12-10

该研究采用群体生理药代动力学/药效学整合分析,将达比加群因药物相互作用及不同程度肾功能导致的暴露变化,与1年内缺血性卒中或大出血事件概率相关联。结果显示:严重肾功能不全者应避免达比加群酯与利托那韦/考比司他合用;中度肾功能不全者需调整剂量或分隔给药;正常肾功能者合用来利托那韦无需调整,合用考比司他应考虑减量。

要点

  • 严重肾功能不全者应避免达比加群酯与利托那韦或考比司他合用。
  • 中度肾功能不全合用利托那韦可间隔2小时给药或将达比加群酯减至110 mg每日两次。
  • 中度肾功能不全合用考比司他时达比加群酯应进一步减至75 mg每日两次。

核心结论

  • 严重肾功能不全者应避免达比加群酯与利托那韦/考比司他合用,中度肾功能不全者需剂量调整或分隔给药。
  • 正常肾功能者合用来利托那韦无需调整达比加群酯剂量,合用考比司他应考虑减至110 mg每日两次。

研究设计与样本

  • 研究采用整合群体生理药代动力学/药效学分析,将达比加群暴露变化与1年内缺血性卒中或大出血事件概率相关联。

主要发现

  • 合用利托那韦或考比司他可增加达比加群暴露,从而增加大出血风险,尤其合并肾功能不全时。
  • 不同肾功能程度下相互作用程度及所需剂量调整不同。

关键数值与推荐

  • 严重肾功能不全:避免达比加群酯与利托那韦/考比司他合用。
  • 中度肾功能不全合用利托那韦:间隔2小时给药或达比加群酯减至110 mg每日两次。
  • 中度肾功能不全合用考比司他:达比加群酯减至75 mg每日两次。
  • 正常肾功能合用利托那韦:无需调整;合用考比司他:考虑减至110 mg每日两次。

临床怎么用

  • 临床对接受利托那韦或考比司他的患者处方达比加群酯前应评估肾功能并按上述情形调整剂量或避免合用。
  • 中度肾功能不全者可优先考虑间隔2小时给药或减量,合用考比司他时需进一步减量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Drug-drug interactions (DDIs) between dabigatran and ritonavir/cobicistat are of major concern in people living with HIV, particularly in those with impaired renal function, because they can result in increased dabigatran exposure and thus an increased risk of major bleeding events. However, the extent of this interaction and subsequent need for dose adjustment in subjects with varying degrees of renal function is currently not yet fully understood. To close this knowledge gap, we conducted an integrated population physiologically-based pharmacokinetic/pharmacodynamic analysis linking changes in dabigatran exposure due to DDIs and varying degrees of renal function to the probability of experiencing an ischemic stroke or major bleeding event within 1 year. The results of our analysis suggest that coadministration of dabigatran etexilate (dabigatran prodrug) and ritonavir/cobicistat should be avoided in subjects with severe renal impairment. A 2-hour dose separation or dabigatran etexilate dose reduction to 110 mg b.i.d. (twice daily) should be considered in subjects with moderate renal impairment when coadministered with ritonavir, while the dabigatran etexilate dose should be further reduced to 75 mg b.i.d. when coadministered with cobicistat. No dabigatran etexilate dose adjustment is needed in subjects with normal renal function receiving ritonavir, but dabigatran etexilate dose reduction to 110 mg b.i.d. should be considered when coadministered with cobicistat.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lingineni K, Farhan N, Kim S, et al. Quantitative Benefit-Risk Assessment of P-gp-Mediated Drug-Drug Interactions of Dabigatran Coadministered With Pharmacokinetic Enhancers in Patients With Renal Impairment. Clin Pharmacol Ther. 2020. PMID: 33073366. doi:10.1002/cpt.2087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。